For the most part, I usually argue here against buying shares of investment companies, but there are exceptions, and American Capital Strategies is one.
American Capital Strategies (NASDAQ: ACAS) invests in middle-market companies through 12 offices in the United States and Europe. Typically, it invests up to $800 million to fund management and employee buyouts, private equity firm buyouts, acquisitions, and restructurings.
Analysts like ACAS's projected asset growth rate for 2008, including alternative assets managed through external funds.
Further, portfolio income should increase via the improved pricing of recent investments; fee income should also perform well, due to fund management business expansion. Analysts also like ACAS's very good track record of returning capital to shareholders. The Reuters F2008/F2009 EPS consensus estimates for ACAS are $3.31/$3.46.
The risks? Analysts are keeping an eye on possible, further write-downs associated with externally managed funds.
The First Call mean rating for ACAS is: Hold [19 firms]. Mean 2008 target: $37 [high: $50, low: $34].
Stock Analysis: American Capital Strategies is a moderate-risk stock not suitable for low-risk investors. Investors with an investment horizon longer than two years should be rewarded from ACAS's shares. Sell/Stop Loss if you were to purchase shares in this company: $22.
Disclosure: Lazzaro has no positions in stocks. In addition to private real estate holdings, he owns corporate and municipal bonds, and cash certificates of deposit.
Last updated: February 13, 2012: 05:02 PM
Hot Stocks
DailyFinance Headlines
- 5 Things to Watch This Week: Cars, Games, Hearts, and a Lot of Z's
- 3 Keys to a Great Balance Transfer Card (and 1 Card That Offers Them)
- Is It Already 'The End' for E-Book Readers?
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
Benzinga Headlines
- Military Budget Cuts Hit These Contractors
- Earnings Preview: Tesla Hoping to Retain its Drive
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
TheFlyOnTheWall.com Headlines
- Ultra Clean sees Q1 EPS 15c-18c vs. consensus 9c
- Health Management reports Q4 same hospital revenue up 5% to $1.42M
- Ultra Clean Q4 EPS included a 28c tax benefit
- Ultra Clean reports Q4 EPS 34c vs. consensus 3c
- Health Management reports Q4 EPS 26c vs. consensus 20c
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 5 Things to Watch This Week: Cars, Games, Hearts, and a Lot of Z's
- 3 Keys to a Great Balance Transfer Card (and 1 Card That Offers Them)
- Is It Already 'The End' for E-Book Readers?
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
5-Hour Energy: A Success Equal Parts Caffeine, Chemistry and…
Suddenly, Amazon Doesn't Love Its Moms Anymore

